CL2024000647A1 - Régimen de dosificación - Google Patents
Régimen de dosificaciónInfo
- Publication number
- CL2024000647A1 CL2024000647A1 CL2024000647A CL2024000647A CL2024000647A1 CL 2024000647 A1 CL2024000647 A1 CL 2024000647A1 CL 2024000647 A CL2024000647 A CL 2024000647A CL 2024000647 A CL2024000647 A CL 2024000647A CL 2024000647 A1 CL2024000647 A1 CL 2024000647A1
- Authority
- CL
- Chile
- Prior art keywords
- dosage regimen
- glp
- glucagon
- peptide
- obesity
- Prior art date
Links
- 102100040918 Pro-glucagon Human genes 0.000 abstract 4
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 abstract 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21194879 | 2021-09-03 | ||
| EP22160234 | 2022-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024000647A1 true CL2024000647A1 (es) | 2024-09-13 |
Family
ID=84272918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000647A CL2024000647A1 (es) | 2021-09-03 | 2024-03-01 | Régimen de dosificación |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250073311A1 (enExample) |
| EP (1) | EP4392054A1 (enExample) |
| JP (1) | JP7860224B2 (enExample) |
| KR (1) | KR20240058121A (enExample) |
| AU (1) | AU2022339044A1 (enExample) |
| CA (1) | CA3228429A1 (enExample) |
| CL (1) | CL2024000647A1 (enExample) |
| IL (1) | IL311166A (enExample) |
| MX (1) | MX2024002600A (enExample) |
| TW (1) | TW202315882A (enExample) |
| WO (1) | WO2023031380A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025248124A1 (en) | 2024-05-31 | 2025-12-04 | Zealand Pharma A/S | Dapiglutide for use in treating a sub-group of subjects |
| WO2026052859A1 (en) | 2024-09-09 | 2026-03-12 | Zealand Pharma A/S | Treatment with dapiglutide |
| WO2026052861A1 (en) | 2024-09-09 | 2026-03-12 | Zealand Pharma A/S | Treatment with dapiglutide |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| CZ295838B6 (cs) | 1996-09-09 | 2005-11-16 | Zealand Pharma A/S | Způsob výroby peptidů |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| CA2361830A1 (en) | 1999-03-17 | 2000-09-21 | Novo Nordisk A/S | Method for acylating peptides and novel acylating agents |
| TWI362392B (en) * | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| KR102502040B1 (ko) | 2016-12-09 | 2023-02-24 | 질랜드 파마 에이/에스 | 아실화 glp-1/glp-2 이중 효능제 |
| AU2017373901B2 (en) | 2016-12-09 | 2021-06-03 | Zealand Pharma A/S | GLP-1/GLP-2 dual agonists |
| WO2018104558A1 (en) * | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
| SG11202111312UA (en) | 2019-06-14 | 2021-12-30 | Zealand Pharma As | Pharmaceutical parenteral composition of dual glp1/2 agonist |
| EP4126003A1 (en) * | 2020-03-30 | 2023-02-08 | Zealand Pharma A/S | Glp-1/glp-2 dual agonists |
| IL301891A (en) * | 2020-12-16 | 2023-06-01 | Zealand Pharma As | Drug composition of dual GLP-1/GLP-2 agonists |
| AU2021399904B2 (en) * | 2020-12-16 | 2024-09-05 | Zealand Pharma A/S | Pharmaceutical composition of glp-1/glp-2 dual agonists |
| TWI921427B (zh) * | 2020-12-16 | 2026-04-11 | 丹麥商西蘭製藥公司 | Glp-1/glp-2雙重促效劑之醫藥組合物 |
-
2022
- 2022-09-02 IL IL311166A patent/IL311166A/en unknown
- 2022-09-02 TW TW111133296A patent/TW202315882A/zh unknown
- 2022-09-02 WO PCT/EP2022/074420 patent/WO2023031380A1/en not_active Ceased
- 2022-09-02 JP JP2024513893A patent/JP7860224B2/ja active Active
- 2022-09-02 MX MX2024002600A patent/MX2024002600A/es unknown
- 2022-09-02 US US18/688,026 patent/US20250073311A1/en active Pending
- 2022-09-02 AU AU2022339044A patent/AU2022339044A1/en active Pending
- 2022-09-02 CA CA3228429A patent/CA3228429A1/en active Pending
- 2022-09-02 KR KR1020247010163A patent/KR20240058121A/ko active Pending
- 2022-09-02 EP EP22805777.4A patent/EP4392054A1/en active Pending
-
2024
- 2024-03-01 CL CL2024000647A patent/CL2024000647A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202315882A (zh) | 2023-04-16 |
| EP4392054A1 (en) | 2024-07-03 |
| KR20240058121A (ko) | 2024-05-03 |
| IL311166A (en) | 2024-04-01 |
| US20250073311A1 (en) | 2025-03-06 |
| CA3228429A1 (en) | 2023-03-09 |
| AU2022339044A1 (en) | 2024-03-14 |
| JP7860224B2 (ja) | 2026-05-15 |
| WO2023031380A1 (en) | 2023-03-09 |
| WO2023031380A9 (en) | 2024-02-22 |
| MX2024002600A (es) | 2024-03-22 |
| JP2024533153A (ja) | 2024-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024002600A (es) | Regimen de dosificacion. | |
| CO2019005924A2 (es) | Agonistas duales acilados de glp-1/glp-2 | |
| CL2008003222A1 (es) | Peptidos con actividad antagonista de glucagon y composicion farmaceutica que los comprende, utiles para el tratamiento de la hiperglicemia, para suprimir el apetito, reducir el aumento de peso y para tratar el desgaste catabolico. | |
| AR134152A2 (es) | Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
| ECSP23095307A (es) | Agonista del receptor de glp-1 y composición y uso del mismo | |
| CL2023000087A1 (es) | Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral | |
| MX2021000793A (es) | Compuestos coagonistas de gip/glp1. | |
| AR069136A1 (es) | Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 (peptido somilar al glucagon tipo 1) y usos de los mismos | |
| MX2026003024A (es) | Agonista multireceptor y uso medico del mismo | |
| PE20211417A1 (es) | Analogos novedosos de glp-1 | |
| CO2021017401A2 (es) | Agonistas de receptor de melanocortina-4 | |
| BR112023024968A2 (pt) | Tratamento da obesidade e distúrbios relacionados à obesidade | |
| CL2012003053A1 (es) | Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad. | |
| PE20251599A1 (es) | Metodos para el tratamiento de la obesidad | |
| PE20170954A1 (es) | Compuestos co-agonistas de gip y glp-1 | |
| GT200600004A (es) | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentracion sanguinea de glp-1 | |
| AR092873A1 (es) | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon | |
| CO2024012792A2 (es) | Compuestos como agonistas de glp-1r | |
| CL2021003266A1 (es) | Anticuerpos de receptor de péptido natriurético 1 y métodos de uso | |
| DOP2001000289A (es) | Combinación de agonistas de gaba e inhibidores de sorbitol- deshidrogenasa | |
| CO2022009510A2 (es) | Compuestos activos frente a receptores nucleares | |
| AR047776A1 (es) | Composiciones farmaceuticas glp - 1 | |
| MX2022009776A (es) | Tratamiento de la colangitis biliar primaria con elafibranor. | |
| UY40349A (es) | Agonista dual de glp-1/gip, método de preparación y uso del mismo | |
| ECSP23071867A (es) | Composiciones que contienen análogos de incretina y usos de estas |